Why the study?
Does gemfibrozil reduce the incidence of coronary heart disease in middle-aged men with lipid abnormalities?
Population
n=4,081 men between 40 and 55 years of age with lipid abnormalities and free from coronary heart disease or…
Comparison
Gemfibrozil 600 mg twice daily and a… vs Matching placebo capsules and a…
Design
RCT, Randomly allocated, Matching placebo
Follow-up
5 years (planned)
Authors
Loading...
This paper describes the design and successful randomization of the Helsinki Heart Study, a primary prevention trial evaluating gemfibrozil in middle-aged men with dyslipidemia.
Does gemfibrozil reduce the incidence of coronary heart disease in middle-aged men with lipid abnormalities?
This paper describes the design and successful randomization of the Helsinki Heart Study, a primary prevention trial evaluating gemfibrozil in middle-aged men with dyslipidemia.
Mänttäri et al. (1987) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: